![Company](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_CMN_Companies_to_Follow_2023_01_17_81d7a58868_1c503a0f51.png)
Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.
Always stay updated with the free CMN Newsletter.
Beam Therapeutics
General information
Main focus: Base editing for the treatment of genetic diseases and cancer
Company stage: Pre-clinical
Diseases: Sickle cell disease, beta-thalassemia, acute lymphoblastic leukaemia (ALL), alpha-1 antitrypsin deficiency, glycogen storage disorder-1, Stargardt disease
Genome-editing tool: Cytosine base editor, adesonine base editor, prime editing
Funding stage: Public (NASDAQ:BEAM)
Location: Cambridge, MA, USA
Website: https://beamtx.com/
Pipeline: https://beamtx.com/our-portfolio/
Partners: Prime Medicine, Verve Therapeutics, Sana Biotechnology, Apellis Pharmaceuticals, Bio Palette
![](https://d2qa4785ekzzy0.cloudfront.net/typo3temp/assets/images/csm_beam_therapeutics_cd52da5fbb_fcf025688b.png)
Beam Therapeutics is developing precision genetic medicines through base editing. Founded by leading scientists from the CRISPR field, Beam is pursuing therapies for serious diseases using its proprietary base-editing technology, which can make precise edits to single base pairs in DNA and RNA. The company's most advanced programme is in IND-enabling studies for sickle cell anaemia.